てんかん(癲癇)治療薬のアジア市場

調査会社GBI Research社が発行したリサーチレポート(データ管理コード:GBIHC484MR)
◆英語タイトル:Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth
◆発行会社/調査会社:GBI Research
◆商品コード:GBIHC484MR
◆発行日:2018年11月
◆調査対象地域:アジア太平洋
◆産業分野:医療・製薬
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,995 ⇒換算¥544,455見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD9,990 ⇒換算¥1,088,910見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD14,985 ⇒換算¥1,633,365見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[てんかん(癲癇)治療薬のアジア市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Epilepsy Therapeutics in Asia-Pacific Markets to 2024 – Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth
Summary

Epilepsy is a chronic disorder of the brain with substantial morbidity. There are more than 65 million people with epilepsy globally, and this is growing because of the rapidly increasing population. The rising prevalence population in Asia-Pacific (APAC) has driven revenue growth.

The morbidity and mortality associated with epilepsy are considerable. Epilepsy has the greatest impact on quality of life of all the chronic diseases, including diabetes, arthritis, and hypertension. Due to social stigma patients are reluctant to visit physicians. The poor long-term prognosis associated with epilepsy has created a pressing need for improved therapeutic options.

The marketed drug landscape contains hydantoins (phenytoin and fosphenytoin), iminostilbenes (carbamazepine and oxcarbazepine), succinimides (ethosuximide), aliphatic carboxylic acid (valproic acid) benzodiazepines (clonazepam, diazepam, lorazepam and clobazam), phenyltriazine (lamotrigine), cyclic GABA analogues (gabapentin and pregabalin), and newer drugs (levetiracetam, vigabatrin, tiagabine, lacosamide, felbamate, rufinamide, and brivaracetam). However, significant unmet need exists for disease-modifying therapies and targeted therapies.

Drugs currently in Phase III are Cenobamate for refectory epilepsy and ZX-008 (low-dose fenfluramine Hydrochloride) for Lennox-Gastaut syndrome. Epidiolex, an FDA-approved first drug comprising an active ingredient derived from marijuana to treat Lennox-Gastaut syndrome, is in the early stages of development in APAC.

Scope

- The APAC epilepsy market will be valued at $1.7 billion in 2024, growing from $1.4 billion in 2017 at a CAGR of 3.5%.
- How will the approval of Cenobamate for treatment-resistant epilepsy affect the competitive landscape, with no therapy currently available to address this patient subset?
- The epilepsy market is crowded with cheap, generic, “me-too” drugs. What are the main barriers a new therapy faces when entering the epilepsy market?
- The pipeline for epilepsy therapy is not diverse in terms of molecule type and molecular targets.
- How have the late-stage therapies performed in clinical trials?
- The level of unmet need in the epilepsy market is high. Will the pipeline drugs fulfill these unmet needs?
- The market forecasts indicate that India and China will contribute the most to the APAC market.
- How will the annual cost of therapy and market size vary between the five assessed APAC markets?
- How will the growing population affect the market?
- How will the various drivers and barriers influence the market over the forecast period?
- Licensing deals are the most common form of strategic alliance in epilepsy, with total deal values ranging from under $0.1m to over $820m.
- How do deal frequency and value compare between target families and molecule types?

Reasons to buy

This report will enable you to:
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the epilepsy market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the epilepsy pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict epilepsy market growth in the five assessed APAC markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the epilepsy deals landscape by analyzing trends in licensing and co-development deals.

*** レポート目次(コンテンツ)***

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Disease Classification 11
2.4 Symptoms 13
2.5 Etiology and Pathophysiology 14
2.5.1 Etiology 14
2.5.2 Pathophysiology 15
2.6 Diagnosis 17
2.6.1 Biomarkers 19
2.7 Prognosis 20
2.8 Treatment Guidelines and Options 21
2.8.1 Treatment Options 21
3 Marketed Products 28
3.1 Overview 28
3.1.1 Aptiom/Zebinix (Eslicarbazepine acetate) – BIAL-Portela 29
3.1.2 Banzel/Inovelon (Rufinamide) – Novartis 30
3.1.3 Briviact (Brivaracetam) – UCB 31
3.1.4 Fycompa (perampanel) – Eisai 32
3.1.5 Keppra (levetiracetam) – UCB 34
3.1.6 Lyrica (pregabalin) – Pfizer 36
3.1.7 Vimpat (lacosamide) – UCB 37
3.1.8 Lamictal (lamotrigine) – GSK 39
3.1.9 Epidiolex (Cannabidiol) – GW Pharmaceuticals 40
3.1.10 Older Generation AEDs 41
3.2 Comparative Efficacy and Safety of Marketed Product 42
4 Pipeline Analysis 44
4.1 Overview 44
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type 44
4.3 Pipeline Distribution by Molecular Target 45
4.4 Promising Pipeline Candidates 48
4.4.1 Fintepla (low-dose fenfluramine Hydrochloride/ZX-008) – Zogenix 48
4.4.2 Cenobamate (YKP3089) – SK Biopharmaceuticals 50
4.5 Comparative Efficacy and Safety of Pipeline Products 52
4.6 Product Competitiveness Framework 53
5 Clinical Trial Analysis 54
5.1 Failure Rate 54
5.1.1 Overall Failure Rate 54
5.1.2 Failure Rate by Phase and Molecule Type 55
5.1.3 Failure Rate by Phase and Molecular Target 55
5.2 Clinical Trial Size 56
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 56
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 57
5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 58
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 59
5.3 Clinical Trial Duration 60
5.3.1 Clinical Trial Duration by Molecule Type 60
5.3.2 Clinical Trial Duration by Molecular Target 61
5.4 Competitive Clinical Trials Metrics Analysis 62
6 Multi-scenario Forecast 64
6.1 Geographical Markets 64
6.2 Asia-Pacific Market 65
6.3 India 66
6.3.1 Treatment Usage Patterns 66
6.3.2 Annual Cost of Therapy 68
6.3.3 Market Size 69
6.4 China 70
6.4.1 Treatment Usage Patterns 70
6.4.2 Annual Cost of Therapy 71
6.4.3 Market Size 72
6.5 Australia 73
6.5.1 Treatment Usage Patterns 73
6.5.2 Annual Cost of Therapy 74
6.5.3 Market Size 75
6.6 South Korea 76
6.6.1 Treatment Usage Patterns 76
6.6.2 Annual Cost of Therapy 77
6.6.3 Market Size 78
6.7 Japan 79
6.7.1 Treatment Usage Patterns 79
6.7.2 Annual Cost of Therapy 80
6.7.3 Market Size 82
7 Drivers and Barriers 83
7.1 Drivers 83
7.1.1 Improved Economy and Affordability Boost the Market 83
7.1.2 Promising Pipeline Products that Target Unmet Needs for Epilepsy 83
7.1.3 Government-Sponsored Increased Awareness and Access to Healthcare will Improve Epilepsy Treatment 83
7.2 Barriers 84
7.2.1 Social Stigma and Lack Awareness to Hamper Low Diagnosis and Treatment Rates 84
7.2.2 Impending Patent Cliffs and Generic Erosion 84
7.2.3 Lack of Strong Patent Protection or Intellectual Property Rights. 84
8 Deals and Strategic Consolidations 85
8.1 Licensing Deals 85
8.1.1 Deals by Region and Value 85
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 86
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 87
8.2 Key Licensing Deals 90
8.3 Co-development Deals 91
8.3.1 Deals by Region and Value 91
8.3.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 92
8.3.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 93
8.4 Key Co-development Deals 96
9 Appendix 98
9.1 All Pipeline Drugs by Stage of Development 98
9.1.1 Discovery 98
9.1.2 Preclinical 99
9.1.3 IND/CTA-filed 103
9.1.4 Phase I 103
9.1.5 Phase II 104
9.1.6 Phase III 105
9.1.7 Pre-registration 106
9.2 Summary of Multi-scenario Market Forecasts to 2024 107
9.2.1 Asia-Pacific 107
9.2.2 India 107
9.2.3 China 107
9.2.4 Australia 108
9.2.5 South Korea 108
9.2.6 Japan 109
9.3 Bibliography 109
9.4 Abbreviations 114
9.5 Research Methodology 116
9.5.1 Secondary Research 117
9.5.2 Marketed Product Profiles 117
9.5.3 Late-Stage Pipeline Candidates 117
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 117
9.5.5 Product Competitiveness Framework 118
9.5.6 Pipeline Analysis 118
9.5.7 Forecasting Model 119
9.5.8 Deals Data Analysis 119
9.6 Contact Us 120
9.7 Disclaimer 120

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2017 12
Table 2: Causes of Epilepsy According to Age 14
Table 3: Examples of Biomarkers Needed in Different Epilepsy Indications 20
Table 4: AED Options by Seizure Type 22
Table 5: Epilepsy Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2018 91
Table 6: Epilepsy Therapeutics Market, Global, Co-development Deals, 2007-2018 97
Table 7: Epilepsy Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 98
Table 8: Epilepsy Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 99
Table 9: Epilepsy Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018 103
Table 10: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 103
Table 11: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 104
Table 12: Epilepsy Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 105
Table 13: Epilepsy Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018 106
Table 14: Epilepsy Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024 107
Table 15: Epilepsy Therapeutics Market, India, Market Forecast, 2017-2024 107
Table 16: Epilepsy Therapeutics Market, China, Market Forecast, 2017-2024 107
Table 17: Epilepsy Therapeutics Market, Australia, Market Forecast, 2017-2024 108
Table 18: Epilepsy Therapeutics Market, South Korea, Market Forecast, 2017-2024 108
Table 19: Epilepsy Therapeutics Market, Japan, Market Forecast, 2017-2024 109

1.2 List of Figures
Figure 1: Epilepsy Therapeutics Market, Patient Distribution in APAC 10
Figure 2: Summary of the Pathophysiology of Seizures by Net Increased Neuronal Excitation 16
Figure 3: Algorithm for investigation of patient presenting with seizure 18
Figure 4: Algorithm for Choice of AED for New-Onset Epilepsy Patients 26
Figure 5: Treatment Algorithm for Status Epilepticus in Australia 27
Figure 6: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 43
Figure 7: Pipeline for Epilepsy Therapeutics, Global, 2018 45
Figure 8: Pipeline for Epilepsy Therapeutics by Molecular Target, Global, 2018 47
Figure 9: Epilepsy Therapeutics Market, APAC, ZX008 Forecast ($m), 2020-2024 50
Figure 10: Epilepsy Therapeutics Market, APAC, Cenobamate Forecast ($m), 2020-2024 51
Figure 11: Epilepsy Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 52
Figure 12: Epilepsy Therapeutics Market, Competitor Matrix for Epilepsy Marketed and Pipeline Products 53
Figure 13: Epilepsy Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017 55
Figure 14: Epilepsy Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017 56
Figure 15: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017 57
Figure 16: Epilepsy Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017 58
Figure 17: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017 59
Figure 18: Epilepsy Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017 60
Figure 19: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017 61
Figure 20: Epilepsy Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017 62
Figure 21: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 62
Figure 22: Epilepsy Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 63
Figure 23: Epilepsy Therapeutics Market, Asia-Pacific, Treatment Patterns (million), 2017-2024 65
Figure 24: Epilepsy Therapeutics Market, APAC, Market Size ($m), 2017-2024 66
Figure 25: Epilepsy Therapeutics Market, India, Treatment Patterns (million), 2017-2024 67
Figure 26: Epilepsy Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 69
Figure 27: Epilepsy Therapeutics Market, India, Market Size ($m), 2017-2024 70
Figure 28: Epilepsy Therapeutics Market, China, Treatment Patterns (million), 2017-2024 71
Figure 29: Epilepsy Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 72
Figure 30: Epilepsy Therapeutics Market, China, Market Size ($m), 2017-2024 73
Figure 31: Epilepsy Therapeutics Market, Australia, Treatment Patterns (‘000), 2017-2024 74
Figure 32: Epilepsy Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 75
Figure 33: Epilepsy Therapeutics Market, Australia, Market Size ($m), 2017-2024 76
Figure 34: Epilepsy Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017-2024 77
Figure 35: Epilepsy Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 78
Figure 36: Epilepsy Therapeutics Market, South Korea, Market Size ($m), 2017-2024 79
Figure 37: Epilepsy Therapeutics Market, Japan, Treatment Patterns (000), 2017-2024 80
Figure 38: Epilepsy Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 81
Figure 39: Epilepsy Therapeutics Market, Japan, Market Size ($m), 2017-2024 82
Figure 40: Epilepsy Therapeutics Market, Global, Licensing Deals By Region And Value, 2007-2018 86
Figure 41: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 87
Figure 42: Epilepsy Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 88
Figure 43: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018 89
Figure 44: Epilepsy Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018 90
Figure 45: Epilepsy Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018 92
Figure 46: Epilepsy Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2008-2018 93
Figure 47: Epilepsy Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 94
Figure 48: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2018 95
Figure 49: Epilepsy Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2018 95

*** 掲載企業 ***



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • ベンゾ(b)フルオランテンの世界市場2019
    The Global Benzo(B)Fluoranthene (CAS 205-99-2) Industry 2019 Market Research Report is a professional and in-depth study on the current state of the Benzo(B)Fluoranthene industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and i …
  • ABS樹脂の世界市場2016
    The Global Acrylonitrile Butadiene Styrene(ABS) Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Acrylonitrile Butadiene Styrene(ABS) industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, a …
  • キシレノールカルボン酸の世界市場
    Xylenol Carboxylic Acid Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States …
  • UTC Nigeria PLC:企業概要・分析
    Synopsis Canadean's "UTC Nigeria PLC - Company Capsule" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, financial ratios, key competitors, financial analysis, key employees as well as compan …
  • 世界主要国における食品用プラスチック容器市場2018-2023
    In 2017, the global Plastic Food Containers market size was xx million USD, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. This report studies Plastic Food Containers in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, …
  • ハンガリーのアルミ箔市場(~2020):市場規模、動向、予測
    The report Aluminium Foil Market in Hungary to 2020 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for aluminium foil in Hungary. The research includes historic data from 2009 to 2015 and forecasts until 2020 whic …
  • 世界のフィナステリド市場2016
    Notes:Production, means the output of Finasteride Revenue, means the sales value of Finasteride This report studies Finasteride in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenu …
  • ヘッドアップディスプレイ(HUD)の世界市場分析:自動車用、航空機用、ウェアラブル
    The global head up displays (HUD) market size is expected to reach USD 13.5 billion by 2025, according to a new report by Grand View Research, Inc. In terms of shipments HUD systems demand would reach 34.87 million units by the year 2025. A Head Up Display is computerized systems that projects infor …
  • メキシコの炭酸塩及びペルオキソ炭酸塩市場2015
    The report presents analysis of carbonates and peroxocarbonates market in Mexico. [Scope] Brief country profile includes general information and main economic indicators and specifies business environment in Mexico Carbonates and Peroxocarbonates market is analyzed by different parameters including …
  • 高齢者介護の世界市場:企業概要・規模・シェア・成長・動向・予測(~2025年)
    Global elderly care market is expected to register a healthy CAGR in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.Prominent factors driving the growth of this market consist …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GBIHC484MR )"てんかん(癲癇)治療薬のアジア市場" (英文:Epilepsy Therapeutics in Asia-Pacific Markets to 2024 - Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth)はGBI Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。